Advertisement
Table 1 Patient characteristics and survival analysis (by clinicopathological subtype)
| Characteristic | Luminal A (n = 119) | Luminal B Ki67+ (n = 52) | Luminal B HER2 + (22) | HER2 overexpression (16) | TNBC (46) | Statistics | P |
|---|---|---|---|---|---|---|---|
| Age (years) | 51.67 ± 10.10 | 50.88 ± 8.16 | 55.41 ± 8.98 | 52.13 ± 6.49 | 51.91 ± 10.90 | 0.896 | 0.467 |
| Menopause | 2.378 | 0.667 | |||||
| Postmenopausal | 56 | 24 | 14 | 7 | 22 | ||
| Premenopausal | 63 | 28 | 8 | 9 | 24 | ||
| Family history | 2.075 | 0.722 | |||||
| No | 109 | 49 | 21 | 16 | 42 | ||
| Yes | 10 | 3 | 1 | 0 | 4 | ||
| Diameter | 2.15 ± 0.98 | 2.32 ± 0.94 | 2.43 ± 1.07 | 3.09 ± 1.49 | 2.50 ± 1.18 | 3.292 | 0.012 |
| Quadrant | 16.851 | 0.395 | |||||
| Areolar | 3 | 1 | 0 | 0 | 1 | ||
| Inner upper | 28 | 8 | 0 | 2 | 7 | ||
| Inner lower | 14 | 5 | 1 | 2 | 3 | ||
| Outer lower | 21 | 11 | 3 | 2 | 6 | ||
| Outer upper | 53 | 27 | 18 | 10 | 29 | ||
| Enhancement patterns | 59.901 | 0.000 | |||||
| Homogeneous | 40(33.6%) | 18(34.6%) | 7(31.8%) | 5(31.3%) | 12(26.1%) | ||
| Heterogeneous | 71(59.7%) | 29(55.8%) | 8(36.4%) | 3(18.8%) | 10(21.7%) | ||
| Peripherals | 8(6.7%) | 5(9.6%) | 7(31.8%) | 8(50.0%) | 24(52.2%) | ||
| Difference of MVD (Edge - Center) | 3.12 ± 6.26 | 3.18 ± 7.95 | 7.61 ± 8.53 | 7.98 ± 8.97 | 10.23 ± 8.72 | 9.543 | 0.000 |
| Grade of DMVD | 42.300 | 0.000 | |||||
| Uniform distribution | 102(85.7%) | 44(84.6%) | 14(63.6%) | 6(37.5%) | 21(45.7%) | ||
| Uneven distribution | 17(14.3%) | 8(15.4%) | 8(36.4%) | 10(62.5%) | 25(54.3%) | ||
| Histological grade | 30.927 | 0.000 | |||||
| I | 37(31.1%) | 16(30.8%) | 0(0%) | 1(6.3%) | 9(19.6%) | ||
| II | 77(64.7%) | 29(55.8%) | 16(72.7%) | 10(62.5%) | 34(73.9%) | ||
| III | 5(4.2%) | 7(13.5%) | 6(27.3%) | 5(31.3%) | 3(6.5%) | ||
| Cancer thrombosis | 7.806 | 0.099 | |||||
| Negative | 89 | 41 | 11 | 10 | 34 | ||
| Positive | 30 | 11 | 11 | 6 | 12 | ||
| Nodal metastasis | 6.825 | 0.145 | |||||
| Negative | 60 | 24 | 8 | 3 | 23 | ||
| Positive | 59 | 28 | 14 | 13 | 23 | ||
| Number of metastatic nodes | 2.09 ± 4.16 | 2.94 ± 5.01 | 6.77 ± 9.63 | 11.88 ± 11.37 | 4.89 ± 9.70 | 9.167 | 0.000 |
| Clinical stage | 50.721 | 0.000 | |||||
| I | 33(27.7%) | 15(28.8%) | 1(4.5%) | 0(0%) | 10(21.7%) | ||
| IIA | 38(31.9%) | 11(21.2%) | 10(45.5%) | 4(25.0%) | 13(28.3%) | ||
| IIB | 39(32.8%) | 21(40.4%) | 4(18.2%) | 4(25.0%) | 16(34.8%) | ||
| IIIA | 7(5.9%) | 3(5.8%) | 3(13.6%) | 3(18.8%) | 2(4.3%) | ||
| IIIB | 1(0.8%) | 2(3.8%) | 2(9.1%) | 1(6.3%) | 1(2.2%) | ||
| IIIC | 1(0.8%) | 0(0%) | 2(9.1%) | 4(25%) | 4(8.7%) | ||
| IV | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | ||
| P53 (%) | 27.76 ± 30.19 | 32.65 ± 34.17 | 41.55 ± 30.32 | 30.19 ± 32.23 | 35.50 ± 35.33 | 1.141 | 0.338 |
| Operation | 5.455 | 0.244 | |||||
| Mastectomy | 102 | 47 | 21 | 16 | 43 | ||
| Tumorectomy | 17 | 5 | 1 | 0 | 3 | ||
| Chemotherapy program | 49.253 | 0.002 | |||||
| Not performed | 1(0.8%) | 0(0%) | 0(0%) | 0(0%) | 1(2.2%) | ||
| CMF | 2(1.7%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | ||
| CAF or AC | 42(35.3%) | 17(32.7%) | 2(9.1%) | 0(0%) | 11(23.9%) | ||
| CEF or EC | 21(17.6%) | 12(23.1%) | 10(45.5%) | 5(31.3%) | 14(30.4%) | ||
| T or TC or TP | 42(35.3%) | 15(28.8%) | 4(18.2%) | 2(12.5%) | 13(28.3%) | ||
| TAC or A-T | 10(8.4%) | 8(15.4%) | 6(27.3%) | 9(56.3%) | 7(15.2%) | ||
| Radiotherapy | 6.682 | 0.154 | |||||
| Not performed | 67 | 27 | 10 | 4 | 27 | ||
| Performed | 52 | 25 | 12 | 12 | 19 | ||
| Endocrine therapy | 262.436 | 0.000 | |||||
| Not performed | 0(0%) | 0(0%) | 0(0%) | 16(100%) | 46(100%) | ||
| TAM | 75(63.0%) | 32(61.5%) | 12(54.5%) | 0(0%) | 0(0%) | ||
| LHRH | 11(9.2%) | 7(13.5%) | 0(0%) | 0(0%) | 0(0%) | ||
| AI | 33(27.7%) | 13(25.0%) | 10(45.5%) | 0(0%) | 0(0%) | ||
| Targeted therapy | 33.619 | 0.000 | |||||
| Not performed | 119(100%) | 52(100%) | 20(90.9%) | 13(81.3%) | 46(100%) | ||
| Performed | 0(0%) | 0(0%) | 2(9.1%) | 3(18.8%) | 0(0%) | ||
| Overall survival | 99.2% | 98.1% | 86.4% | 87.5% | 91.3% | 17.629 | 0.024 |
| Event | 1 | 1 | 3 | 2 | 4 | ||
| Deaths | 1 | 1 | 3 | 2 | 3 | ||
| Lost to follow-up | 0 | 0 | 0 | 0 | 1 | ||
| Median survival time | 54.0 | 48.0 | 36.0 | 29.4 | 35.2 | 31.845 | 0.000 |
| Disease-free survival | 98.3% | 94.3% | 72.7% | 75.0% | 82.6% | 56.588 | 0.001 |
| Event | 2 | 3 | 6 | 4 | 7 | ||
| Local recurrence | 0 | 1 | 0 | 0 | 0 | ||
| Contralateral breast cancer | 1 | 1 | 2 | 0 | 0 | ||
| Lung metastasis | 0 | 0 | 0 | 1 | 1 | ||
| Hepatic metastasis | 0 | 0 | 2 | 1 | 2 | ||
| Brain metastasis | 0 | 0 | 0 | 1 | 2 | ||
| Multi-organ | 1 | 1 | 2 | 1 | 2 | ||
| Lost to Follow-up | 0 | 0 | 0 | 0 | 1 | ||
| Disease-free survival | 54.0 | 48.0 | 35.4 | 22.5 | 31.7 | 59.248 | 0.000 |
| Follow-up time | 4.741 | 0.001 | |||||
| Median | 23.0 | 25.5 | 30.5 | 17.0 | 20.0 | ||
| Range | 12-59 | 12-49 | 12-38 | 12-25 | 12-53 |
